Project R-1435

Clinical and preclinical research of the effect of cellular mediators on the modulation of pathogenic responses in multiple sclerosis (Research)

In this project, we want to further investigate and exploit the capacity of DC and Treg to correct or modulate pathogenic responses in MS patients. Current research will provide the foundation for the eventual development of a cellular vaccine for the treatment of MS. Depending on the results of this study it can be envisaged te treat patients suffering from MS with tolerogenic DC and/or immosuppressive Treg in order to eliminate or inactivate autoreactive T-cells.

01 January 2009 - 31 December 2012